For Research Use Only — Not for human or veterinary use.

Education

SS-31: Mitochondria-Targeted Peptide Research in Oxidative Stress Models

A research overview of the cardiolipin-binding tetrapeptide SS-31 (elamipretide), its proposed inner-mitochondrial-membrane mechanism, and the metabolic and cardiac research domains it has been studied in.

SS-31
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.

Key Takeaways

  • SS-31 (also studied under the name elamipretide) is a synthetic aromatic-cationic tetrapeptide that concentrates in mitochondrial membranes at levels reported thousands of times higher than the surrounding cytosol.[2]
  • Its proposed mechanism involves selective binding to cardiolipin, a phospholipid in the inner mitochondrial membrane, stabilizing membrane structure rather than acting as a conventional free-radical-scavenging antioxidant.[1]
  • In a type 2 diabetes cell model, SS-31 was reported to modulate oxidative stress, endoplasmic reticulum stress, and autophagy markers.[3]
  • A long-term clinical trial (TAZPOWER) studied elamipretide in Barth syndrome, a genetic disorder involving reduced cardiolipin levels, reporting improvements in muscle strength during an open-label extension phase.[4]
  • Elamipretide subsequently received FDA accelerated approval in September 2025 as a prescription therapy for Barth syndrome — noted here as regulatory context; vials sold under this catalog's SS-31 listing are supplied strictly for laboratory research use and are not the approved pharmaceutical product.

What It Is

SS-31 is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH₂, also studied in clinical literature under the name elamipretide. It was designed specifically to concentrate in mitochondrial membranes, with research reporting accumulation at levels roughly 1,000 to 5,000 times higher than the surrounding cytosol — a targeting property distinct from most peptides in this catalog, which do not concentrate selectively in a specific organelle.[2]

Mechanism & Pathway

SS-31's proposed mechanism centers on selective binding to cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane that is essential for the proper structure of the protein complexes involved in ATP production. Biophysical research reports that SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism, stabilizing mitochondrial cristae structure.[1] This distinguishes SS-31 mechanistically from conventional antioxidants: rather than neutralizing reactive oxygen species after they form, SS-31 is studied for protecting the structural integrity of cardiolipin itself, which becomes oxidized and destabilized under conditions of aging, disease, or ischemic injury in the research models studied.

Research Domains

  • Mitochondrial membrane biophysics research — studies using lipid bilayer models report SS-31 binding cardiolipin and modulating membrane surface electrostatics.[1]
  • Metabolic & oxidative stress research — a type 2 diabetes cell model reported SS-31 modulating oxidative stress, endoplasmic reticulum stress, and autophagy markers.[3]
  • Genetic mitochondrial disorder research — a long-term clinical trial in Barth syndrome — a genetic disorder involving reduced cardiolipin levels — reported improvements in muscle strength measures during an open-label extension phase.[4]
  • Pharmacological review literature — a 2025 review summarizes elamipretide's structure, mechanism, and studied therapeutic research domains.[2]

Comparative Notes

SS-31 is mechanistically distinct from the other mitochondria-related compounds in this catalog. Where MOTS-c is a mitochondrial-genome-encoded peptide studied for AMPK-linked metabolic signaling, SS-31 is a synthetic peptide studied for direct physical binding to cardiolipin within the inner mitochondrial membrane — a structural rather than signaling mechanism.

SS-31 product page →

Certificate of Analysis: What to Look For

A Certificate of Analysis for an SS-31 research vial should report, at minimum: confirmed amino acid sequence (typically via mass spectrometry) and net peptide content. Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.

References

  1. Mitchell W, Ng EA, Tamucci JD, Boyd KJ, Sathappa M, Coscia A, Pan M, Han X, Eddy NA, May ER, Szeto HH, Alder NN (2020). The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. PMID: 32273339
  2. Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, Santulli G (2025). Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences. PMID: 39940712
  3. Escribano-López I, de Marañon AM, Iannantuoni F, López-Domènech S, Abad-Jiménez Z, Díaz P, Solá E, Apostolova N, Rocha M, Víctor VM (2019). The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes. Journal of Clinical Medicine. PMID: 31466264
  4. Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. PMID: 38602181

FAQ

SS-31 (elamipretide) is a synthetic aromatic-cationic tetrapeptide designed to concentrate selectively in mitochondrial membranes.[2]

Research centers on selective binding to cardiolipin, a phospholipid in the inner mitochondrial membrane, stabilizing membrane structure rather than directly scavenging free radicals.[1]

Yes. A long-term trial (TAZPOWER) studied elamipretide in Barth syndrome, a genetic disorder involving reduced cardiolipin levels, reporting improvements in muscle strength measures during long-term follow-up.[4]

Elamipretide received FDA accelerated approval in September 2025 as a prescription therapy for Barth syndrome, under a specific approved formulation and indication. Vials sold under this catalog's SS-31 listing are a separate, non-clinical research product supplied strictly for laboratory research use — not the approved pharmaceutical product.

A COA for an SS-31 research vial should report confirmed amino acid sequence and net peptide content, consistent with the documentation standard used across this catalog.

No. The SS-31 product in this catalog is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance for this product.

Related Guides